Reviewing TFF Pharmaceuticals (NASDAQ:TFFP) and Ra Pharmaceuticals (NASDAQ:RARX)
TFF Pharmaceuticals (NASDAQ:TFFP) and Ra Pharmaceuticals (NASDAQ:RARX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.
This table compares TFF Pharmaceuticals and Ra Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
5.2% of TFF Pharmaceuticals shares are held by institutional investors. 4.3% of Ra Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares TFF Pharmaceuticals and Ra Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Ra Pharmaceuticals||$3.00 million||724.92||-$102.69 million||($2.31)||-19.89|
TFF Pharmaceuticals has higher earnings, but lower revenue than Ra Pharmaceuticals.
This is a summary of recent recommendations for TFF Pharmaceuticals and Ra Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
TFF Pharmaceuticals currently has a consensus target price of $15.00, suggesting a potential upside of 257.14%. Ra Pharmaceuticals has a consensus target price of $47.38, suggesting a potential upside of 3.10%. Given TFF Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts clearly believe TFF Pharmaceuticals is more favorable than Ra Pharmaceuticals.
TFF Pharmaceuticals beats Ra Pharmaceuticals on 6 of the 8 factors compared between the two stocks.
TFF Pharmaceuticals Company Profile
TFF Pharmaceuticals, Inc., an early-stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. It intends to initially focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company was founded in 2018 and is based in Austin, Texas.
Ra Pharmaceuticals Company Profile
Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is Zilucoplan, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of generalized myasthenia gravis (gMG); has completed Phase II clinical trial for treating paroxysmal nocturnal hemoglobinuria (PNH); and has completed Phase Ib clinical trial to treat patients with renal impairment. The company's pre-clinical programs include Factor D inhibition for treating C3 glomerulonephritis and dense deposit disease; and inhibitors of other complement factors for renal, autoimmune, and central nervous system diseases. It has collaboration and license agreement with Merck & Co., Inc. to identify orally available cyclic peptides for non-complement program targets, and provide research and development services. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for TFF Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TFF Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.